首頁 › 非小細胞肺癌 › 維吉尼亞州 › Richmond
Richmond, VA 的 非小細胞肺癌 臨床試驗
25 項針對 非小細胞肺癌 的研究正在 Richmond（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
招募中3 期
- VCU Health Adult Outpatient Pavillion ( Site 0193), Richmond
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
招募中3 期
- Virginia Cancer Institute, Richmond
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
招募中3 期
- Local Institution - 0337, Richmond
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
招募中3 期
- VCU Medical Center Gateway Building, Richmond
- Virginia Commonwealth University, Richmond
- VCU Health Short Pump Pavilion, Richmond
- 還有 4 項
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
招募中1/2 期
- VCU Medical Center Gateway Building, Richmond
- Virginia Commonwealth University, Richmond
- VCU Health Stony Point, Richmond
- 還有 2 項
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
招募中3 期
- VCU Health Adult Outpatient Pavillion, Richmond
Pan-tumor MRD Study
招募中觀察性研究
- Virginia Cancer Institute, Richmond
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
招募中3 期
- Research Site, Richmond
- Research Site, Midlothian · 距離 11 英里
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
招募中2/3 期
- VCU Massey Cancer Center, Richmond
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
招募中2/3 期
- Virginia Commonwealth University (Vcu), Richmond
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
招募中3 期
- Clinical Study Site, Richmond
- Clinical Study Site, Richmond
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
招募中2/3 期
- Virginia Cancer Institute - West End, Richmond
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
招募中3 期
- VCU Health Adult Outpatient Pavillion, Richmond
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
招募中3 期
- Research Site, Midlothian · 距離 11 英里
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
招募中3 期
- Virginia Commonwealth University, Richmond
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
招募中3 期
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
招募中2 期
- VCU Medical Center (Virginia Commonwealth University), Richmond
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- Virginia Commonwealth University, Richmond
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
招募中2/3 期
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
招募中2 期
- Virginia Commonwealth University, Richmond
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
招募中2 期
- Virginia Commonwealth University, Richmond
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
招募中觀察性研究
- VCU Massey Cancer Center at Stony Point, Richmond
- Virginia Commonwealth University/Massey Cancer Center, Richmond
Repositioning Immunotherapy in VetArans With Lung Cancer
招募中2 期
- Richmond VA Medical Center, Richmond, VA, Richmond
其他城市的 非小細胞肺癌 試驗
- Houston, TX145 項研究
- New York City, NY121 項研究
- Arlington, VA104 項研究
- Nashville, TN97 項研究
- Boston, MA90 項研究
- Los Angeles, CA87 項研究
- St. Louis, MO73 項研究
- Chicago, IL61 項研究
- Baltimore, MD60 項研究
- San Antonio, TX59 項研究
- Columbus, OH57 項研究
- Washington, DC55 項研究
Richmond 的其他研究
- 乳癌26 項研究
- 前列腺癌19 項研究
- 心臟衰竭16 項研究
- 肺癌14 項研究
- 心血管疾病13 項研究
- 大腸直腸癌13 項研究
- 脂肪性肝病12 項研究
- 急性髓系白血病12 項研究
- 轉移性癌症12 項研究
- 頭頸部鱗狀細胞癌12 項研究
- 黑色素瘤11 項研究
- 肥胖症11 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。